577 results about "Lipid Body" patented technology

This invention relates to in-situ preparation of the derivatives of various hydroxy acids (HA), such as alpha-(Alpha) Hydroxy Acids (AHA), beta-(Beta) Hydroxy Acids (BHA), and Poly-Hydroxy Acids (PHA) with certain skin beneficial organic hetero-atom bases and their application in skin resurfacing (exfoliation), and in the synergistic treatment and regulation of topical disorders of skin such as skin aging, wrinkles, acne, rosacea, age-spots, canker sores, striae distensae (stretch marks), pimples, skin redness, and dry skin conditions of cracking, flaking, and scaling. Most HA derivatives produced by the in-situ method do not cause skin irritation and skin redness effects that are commonly experienced with AHA and BHA, yet there is no loss of their skin beneficial effects. These compositions can be traditional water and oil emulsions, liposomes, suspensions, colloids, solutions, masks, muds, serums, sprays, gels, lotions, creams, cleansers, and anhydrous systems, thus offering a wide choice of formulations to meet their consumer appeal and acceptance requirements.

The present invention is based on the discovery of a set of genes that are involved in lipid-droplet formation and regulation. Accordingly, the present invention provides methods of increasing or decreasing lipid concentrations in eukaryotic cells by decreasing or increasing expression of one of these genes. Increased lipid concentrations may be useful, for example, in the generation of biofuels. Decreased lipid concentration may be useful in the treatment of diseases characterized by excessive lipid storage. In addition, the invention provides methods of identifying markers of diseases characterized by excessive lipid storage.

Personal care and hygiene formulations for topical application to mucosal surfaces. These formulations include an amphiphilic lipid carrier in the form of a colloidal composition which can include a micellar aggregate or mixed micelles dispersed in a continuous aqueous phase, or an emulsion of lipid droplets suspended in a continuous aqueous phase, and an active agent which is an anti-microbial agent. The lipid carrier has high adhesiveness to mucous membranes such as the soft tissues of the oral cavity. The lipid carrier also has a high load capacity for the active agent to be carried to these tissues. These formulations have the desirable properties of carrying a large amount of active agent for controlled and prolonged release thereof at the desired site, such as mucous membrane surfaces and surrounding tissue. Accordingly, the present invention provides a formulation for oral or topical application including an anti-microbial agent and a lipid. The agent is held by the carrier through a hydrophobic interaction and is released from the carrier in a controlled manner over a prolonged period of time. The lipid is also characterized by having a high adhesive capability towards mucous membrane surfaces. The lipid and the agent are preferably present in a ratio in a range of from about 1:10 to 10:1, more preferably from about 1:5 to about 5:1, and most preferably from about 1:3 to about 3:1 in the formulation.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

In a preferred embodiemnt the present invention features a composition and method of delivery comprising Glycosaminoglycans encapsulated in a liposomal delivery system for intraarticular administration for the treatment of osteoarthritis In a more preferred embodiemnt the present invention features a composition and method of delivery comprising hyaluronic acid encapsulated in a liposomal delivery system for intraarticular administration for the treatment of osteoarthritis.

Exemplary embodiments of the present disclosure include a combined catheter-based optical coherence tomography-two-photon luminescence (OCT-TPL) imaging system. Exemplary embodiments further include methods to detect, and further characterize the distribution of cellular components (e.g., macrophage, collagen/elastin fiber, lipid droplet) in thin-cap fibroatheromas with high spatial resolution in vivo.

The invention provides a ratio type fluorescent probe for distinguishing lipid droplets with different polarities. A chemical name is (E)-7-(N,N-diethylamino)-3-(3-(4-(diphenylamine)phenyl)acrylyl-2H-benzopyrone; N,N-diethylamino salicylic aldehyde reacts with ethyl acetoacetate to generate 3-acetyl-7-(diethylamino)coumarin; the product reacts with 4-(N,N-Diphenylamino)benzaldehyde (4) to obtain the fluorescent probe. The fluorescent probe has a two-photon property and an aggregation-induced light-emitting property; a whole body of the probe is electrically neutral and can be positioned in thelipid droplets with the different polarities very well. The probe has low toxicity, good optical stability and specific response on the polarities; detection on the polarities of the lipid droletps in organs and living bodies is realized. The invention further provides a synthesis method of the probe; the synthesis method has the advantages of simple steps, convenient for purification and high yield.

The invention provides liposomal particle compositions, which incorporate a lipophilic biodegradable polymer, such as amino acid-containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU), throughout the particles to stabilize the composition for in vivo delivery in of an incorporated biologic agent. For oral delivery, a biologic, such as insulin, is conjugated directly to the polymer. Lipids in the particle are selected to further stabilize the composition during fabrication and digestion, providing sustained delivery of the biologic with native activity. Methods of making and using the invention compositions to administer the biologic agent in vivo are also included.

The present invention relates to compositions and methods for intracellular protein delivery. The compositions include a protein operatively associated with a cationic lipid in such a way as to facilitate intracellular delivery of the protein by the cationic lipid, such as by associating directly with a cationic lipid, encapsulating it in a cationic liposome, associating the protein with a lipoplex comprising cationic lipid and nucleic acid, or associating the protein with an anionic polymer that is in association with a cationic lipid. These compositions are useful in delivering antibodies to intracellular proteins to neutralize their activity, and to introduce therapeutically useful proteins, peptides or small molecules.

The invention relates to preparation and an application of a biodegradable thermosensitive in-situ hydrogel. The hydrogel is prepared by the following steps: by taking a water soluble amphiphilic thermosensitive block polymer polybutyrolactone lactide-polyethylene glycol-polymer polybutyrolactone lactide as a carrier material, dispersing or dissolving the medicine in aqueous liquor thereof; or dispersing particles such microballoon, lipidosome and emulsion droplets which load the medicine in the aqueous liquor. When the temperature is lower than the phase inversion temperature, the hydrogel exists in form of a liquid which can be delivered by way of injection and the like. When temperature at the delivery part is raised to body temperature, the hydrogel gelates and the medicine is slowly released by way of diffusion or/and corrosion, and the release rate of the medicine can be adjusted by changing concentration, molecular weight, proportion of hydrophilic blocks and hydrophobic blocks or block constitution of the polymer. The hydrogel can be delivered by way of eyes, transdermal delivery, vagina, urethra, rectum, nasal cavity and ears.

The invention discloses an amphiphilic lipid-droplet fluorescent probe with super-high selectivity. The amphiphilic lipid-droplet fluorescent probe with super-high selectivity is characterized in that chemical name of the probe is 1-(3'-(7'-nitrobenzofurazan-4'-)aminopropyl)-2,3,3-trimethylindole bromine, NII for short; and the general chemical formula is as shown in the formula (I). The invention also discloses application of the probe in specifically marking or displaying the form and distribution of lipid droplets in living cells or tissues. Experiments confirm that the probe of the invention is a brand-new probe, has a wide range of application, has good single- and two-photon photostability, fast staining speed and low cytotoxicity, can specifically image lipid droplets in living cells and has a wide application prospect.

The invention relates to a novel preparation method of anthocyanin lipidosome, which solves the problems of poor stability and low bioavailability of free anthocyanin. Based on the characteristic that the stability of anthocyanin is greatly affected by pH, the method adopts the combination of pH gradient and reverse evaporation to obtain anthocyanin lipidosome suspension, and then the anthocyanin lipidosome suspension is subjected to membrane extrusion or circular high-pressure homogenization to obtain the anthocyanin lipidosome with different particle size ranges. As the anthocyanin lipidosome suspension is difficult to store, a freeze-drying protective additive is added during preparation of the lipidosome to pre-freeze the suspension at -65 DEG C and then to freeze and dry the suspension in a freezer dryer, so that freeze-dried anthocyanin lipidosome powder is obtained. The anthocyanin lipidosome prepared by the method has a high embedding rate reaching up to 85.88%, the lipidosome within a particle size range from 100nm to 234nm can be obtained by different processing methods, and the embedding rate of the lipidosome after freeze-drying and redissolving can reach 82.5%. The anthocyanin is improved in in-vivo stability and bioavailability after being embedded by the lipidosome.

The invention relates to an anti-tumor targted lipidosome decorated by pH sensitive polypeptide. The lipidosome is mainly prepared by phospholipid, cholesterol, lipid-polyethylene glycol and lipid-polyethylene glycol-pH sensitive polypeptide. The pH sensitive polypeptide can have enhanced transmembrane capacity in an acidified environment of tumor tissue, and the lipidosome can be mediated to efficiently enter a cell on a tumor part.

The invention discloses a compound with an aggregation induced luminescence property and a preparation method and application thereof in lipid droplet targeting light activating fluorescence imaging. The structure of the compound and the structure of an intermediate product of the compound are represented as the formula I and the formula II, and the formula I can be converted to generate the formula II under the light condition. The compound in the formula I is prepared through the following steps that a compound in the formula III and a compound in the formula IV are dissolved in acetonitrile under the protection of nitrogen, light avoiding reaction is conducted, and the 1,2-dihydro-2-diphenyleneimine ketone compound in the formula I is generated. The novel compound with the aggregation induced luminescence property has the aggregation induced luminescence advantage and can effectively overcome the aggregation induced quenching defect of traditional fluorescent dye, and thus lipid droplet targeting specificity light activating fluorescence imaging in a living cell can be achieved; in addition, the compound has the advantages that the light activating efficiency and the signal-to-noise ratio are high, the cytotoxicity is small, the Stokes shift is large, and the capability of the compound to enter cells is high; and cancer cells and normal cells can be effectively distinguished.

The invention discloses a cell lipid droplet specific-labeling fluorescent probe. The fluorescent probe has a chemical name of 1-(3'-(7'-nitrobenzofuran-4'-)aminopropyl)-4-methylpyridine bromide and has a general chemical formula shown in the formula (I). The invention also discloses a use of the fluorescent probe in specific labeling or display of a lipid droplet form and distribution in living cells. An experiment result shows that the cell lipid droplet specific-labeling fluorescent probe has the characteristics of very high selectivity, background noise-free imaging, two-photon performances, very good light stability, fast dyeing ability, no use of washing and low cytotoxicity and has a great application prospect.

This invention belongs to chemistry pharmaceutical field and relates to a medication transfer system, especially relates to an agglutinin masked medication-load transfer mechanism transferring from nose to brain. This invention comprises medication carrier nanograin, vesicle or lipid body surface finish agglutinin. By using the transfer system, resort time of medication-load system on nasal mucosa can be prolonged, dielectric mucosa absorb the medication-load system and selectively deliver small molecular chemistry medication, diagnosis medication, polypeptide proteins and gene medication into brain. This invention can deliver more medication into brain and relatively decrease medication in outer tissue, so it can depress toxic action at every pore while toning up prevention, cure and diagnosis effect of backbone diseases.

The invention discloses a protein-polysaccharide glass slow releasing microball preparing method of low-temperature water phase-water phase emulsion, which comprises the following steps: allocating water-phase-water-phase emulsion; freezing the emulsion; freeze-drying the sample to obtain the protein-polysaccharide glass; dispersing the micro-particle of protein-polysaccharide in the primary emulsion of oil-soluble macromolecular solution; forming water-in-oil in the water-phase; or forming primary emulsion to decompose macromolecular solution; spraying to dry; adding addictive in the gel; fitting for peptide, antibody or grease body agent.

The invention belongs to the field of medicament preparations, and discloses an octreotide acetate lipidosome precursor and a preparation method thereof. The precursor lipidosome contains octreotide acetate, negatively-charged phospholipid and a cryoprotectant, and can contain an appropriate quantity of other lipids including phosphatidylchline and cholesterol; components such as an antioxidant, a pH regulating agent and the like can be added as required; the molar ratio of the octreotide acetate to the negatively-charged phospholipid is smaller than 1:1; and the mass ratio of the negatively-charged phospholipid to the cryoprotectant is 1:1-1:10. In the invention, a tert-butyl alcohol-water cosolvent freeze-drying method is adopted. The entrapment rate of an octreotide acetate lipidosome/micelle obtained by hydrating a freeze-dried product can be over 50 percent, an octreotide acetate lipidosome/micelle obtained by hydrating the freeze-dried product has high stability, and the problem of difficulty in entrapping a protein polypeptide medicament during preparation of a lipidosome/micelle preparation is solved. The preparation method is simple and practicable, and is suitable for industrial mass production.

The invention relates to a method for preparing a dual-function targeting quantum dot lipidosome. The method comprises the following steps: preparing a single quantum dot lipidosome: dissolving phospholipid, cholesterol, methoxy polyethylene glycol-phospholipid complex and NRP-1 ligand polypeptide polyethylene glycol phospholipid complex into chloroform to obtain a uniform lipid membrane, and drying the chloroform by evaporation; dissolving in an ammonium sulfate solution of quantum dots, and oscillating to obtain lipidosome suspension; extruding, and diluting with normal saline to obtain an active targeting lipidosome containing the quantum dots; adding the active targeting lipidosome containing the quantum dots into an adriamycin normal saline solution, and treating in a water bath for 20 minutes at the temperature of 60 DEG C; and diluting with normal saline through a SephadexG-50 gel column, removing free medicaments, and thus obtaining the dual-function targeting quantum dot lipidosome. The lipidosome prepared by the method can be used for marking and treating glioma cells.

The present invention provides a fluorescent probe and application thereof. The probe which is of an electronic structure of a donor-Pi-receptor has twisted intramolecular charge transfer and aggregation-induced luminescence, and can be excited by two-photon. The probe can help overcome a self-absorption problem caused by large commercial lipid droplet fluorescent dye background and small Stokes'displacement and is high in biocompatibility, high in brightness, low in background and good in light stability. At the same time, a two-photon excitation process is used in the probe, autofluorescence can be lowered, a signal-to-noise ratio can be improved, and a three-dimensional resolution and light stability can be improved; the probe proposed in the invention can be applied to lipid droplet imaging of various cells and tissue sections.

The invention relates to an enzymatically decomposed clam oligopeptide having a recovery effect on a non-alcoholic fatty liver disease (NAFLD) cell model. The clam oligopeptide is characterized by comprising an amino acid sequence of Gln Leu Asn Trp Asp. The invention also relates to a preparation method of the enzymatically decomposed clam oligopeptide having the recovery effect on the NAFLD cell model. Compared with the prior art, the following advantages can be achieved: the NAFLD cell model is established by virtue of induction of palmitic acid and the damaged liver cells in a body are simulated sufficiently, and the result indicates that the TG content of the in-vitro NAFLD cell model established 48 hours after induction by 15 micrograms/milliliter palmitic acid increased remarkably in comparison with that of normal liver cells; oil red O staining shows that the number of intracellular lipid droplets of the model group is increased in contrast with that of the cells of a normal group, and the cell mortality rate is low and the repeatability is good, and therefore, the modeling method is simple, convenient and feasible; meanwhile, the enzymatically decomposed clam oligopeptide having the obvious recovery effect on the NAFLD cell model can be separated out from clams.